MedTrace Logo

Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia

NCT01143389 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 510

Last updated 2018-06-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light to treat progressive keratoconus or post-refractive corneal ectasia.

Conditions

  • Keratoconus
  • Post-Refractive Ectasia

Interventions

DRUG

Riboflavin

Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.

DEVICE

UVX light

UVX 365 nm wavelength light source is applied with continued application of riboflavin.

Sponsors & Collaborators

  • Price Vision Group

    lead INDUSTRY

Principal Investigators

  • Francis W Price, MD · Price Vision Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2017-05-30
Completion
2017-08-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01143389 on ClinicalTrials.gov